UnitedHealth has reached a tentative settlement with the Federal Trade Commission in a lawsuit alleging the company's pharmacy benefit manager inflated insulin costs. The proposed deal follows a similar settlement CVS Health reached with the FTC several months earlier in the same case. The FTC's lawsuit targeted major PBMs for practices allegedly driving up patient costs for insulin products. Specific terms of the UnitedHealth settlement have not been disclosed and remain subject to approval.
Why it mattersMedicaid managed care organizations contracting with UnitedHealth's PBM may face changes to insulin pricing structures, formulary management practices, or rebate pass-through arrangements depending on settlement terms.
Pharmacy · Managed Care
A newborn in Arizona was diagnosed with congenital syphilis after the mother could not access penicillin through Pfizer's emergency allocation program during a national drug shortage. The case illustrates how supply chain disruptions and access barriers to penicillin — the only FDA-approved treatment for syphilis in pregnancy — are contributing to rising congenital syphilis rates. The CDC reported over 3,700 congenital syphilis cases in 2022, up from 335 in 2012. Medicaid covers approximately 42% of all births nationally and a disproportionate share of pregnancies affected by syphilis, making prenatal screening and treatment access critical managed care quality measures.
Why it mattersCongenital syphilis is a HEDIS-tracked preventable birth outcome; MCOs must ensure network providers can access penicillin and complete prenatal screening protocols to avoid adverse birth outcomes and associated NICU costs averaging $20,000 per case.
Maternal · Managed Care · Pharmacy
A Bipartisan Policy Center report finds that most health AI tools currently deployed in healthcare settings operate outside existing regulatory frameworks. The report maps oversight gaps across federal agencies and identifies clinical AI scribes and prior authorization tools as examples of widely used applications with unclear regulatory authority. The analysis highlights inconsistencies in how different types of AI tools are classified and overseen by FDA, ONC, OCR, and other agencies. For Medicaid managed care organizations, the findings underscore the need for internal governance frameworks for AI utilization review, clinical documentation, and administrative automation tools until federal oversight clarifies.
Why it mattersMedicaid managed care organizations deploying AI tools for prior authorization, utilization management, or documentation face uncertain regulatory expectations and potential compliance risk as federal oversight frameworks evolve.
Managed Care
KFF Health News journalists appeared on national and local media outlets to discuss recent stories on medical neglect in ICE detention facilities and comments by Robert F. Kennedy Jr. regarding antidepressants. The media appearances covered investigative reporting on healthcare conditions in immigration detention and public health policy commentary. These discussions occurred as part of KFF Health News's ongoing coverage of healthcare access and policy issues. The appearances reflect broader public interest in healthcare delivery in detention settings and federal health policy discourse.
Why it mattersThis has no direct operational, financial, or compliance implications for Medicaid managed care organizations.